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Abstract
There is now a consensus, based on histological, biochemical and spectral absorption data, that 
the yellow colour observed at the macula lutea is a consequence of the selective accumulation of 
dietary xanthophylls in the central retina of the living eye. Scienti c research continues to explore 
the function(s) of MP in the human retina, with two main hypotheses premised on its putative 
capacity to (1) protect the retina from (photo)-oxidative damage by means of its optical  ltration 
and/or antioxidant properties, the so-called protective hypothesis and (2) in uence the quality of 
visual performance by means of selective short wavelength light absorption prior to photoreceptor 
light capture, thereby attenuating the effects of chromatic aberration and light scatter, the 
so-called acuity and visibility hypotheses. The current epidemic of age-related macular 
degeneration has directed researchers to investigate the protective hypothesis of MP, while there 
has been a conspicuous lack of work designed to investigate the role of MP in visual performance. 
The aim of this review is to present and critically appraise the current literature germane to the 
contribution of MP, if any, to visual performance and experience.
© 2010 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
El pigmento macular y su contribución al rendimiento y experiencia visuales
Resumen
En la actualidad, en función de los datos histológicos, bioquímicos y de la absorción espectral, se 
ha alcanzado un consenso, de que el color amarillo observado en la mácula lútea es consecuencia 
de la acumulación selectiva de xantó los dietéticos en la retina central del ojo vivo. La investiga-
ción cientí ca continúa examinando las funciones del pigmento macular en la retina humana, con 
dos hipótesis principales formuladas sobre su supuesta capacidad para: 1) proteger la retina fren-
te a la lesión (foto)oxidativa por medio de sus propiedades de  ltración óptica y/o antioxidantes, 
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la llamada hipótesis protectora e 2) in uir en la calidad del rendimiento visual por medio de la 
absorción selectiva de luz de longitud de onda corta antes de su captura por parte de los fotorre-
ceptores, lo que atenúa los efectos de la aberración cromática y dispersión de la luz, la llamada 
hipótesis de la agudeza y la visibilidad. La epidemia actual de degeneración macular relacionada 
con la edad ha dirigido a los investigadores a examinar la hipótesis protectora del pigmento macu-
lar, mientras que es evidente la falta de investigación destinada a investigar el papel del pigmento 
en el rendimiento visual. El objetivo de la presente revisión es describir y valorar de forma crítica 
los estudios publicados actuales pertinentes a la contribución del pigmento macular, si desempeña 
algún papel, en el rendimiento y experiencia visual.
© 2010 Spanish General Council of Optometry. Publicado por Elsevier España, S.L. Todos los derechos 
reservados.
Introduction
Vision, and how we perceive the world, involves the complex 
interaction of physical, physiological and psychological 
processes, which ultimately provide the  nal sensation of 
seeing. “Visual performance”, as discussed here, describes 
the sensitivity of the eye where limits of vision are quanti ed 
using established clinical and laboratory techniques. Such 
techniques cannot readily account for variable and highly 
individual experiences and interactions in the real world. 
“Visual experience” incorporates subjective experience, 
which may, for example, explain inconsistencies between 
patient’s symptoms and measured functional vision. Any 
influence of macular pigment (MP) on vision needs to be 
assessed therefore, in terms of both measured performance 
and reported experience.
Macular pigment was  rst observed by Buzzi 1 in 1782, and 
speculation persists as to its role in the visual system. 
Indeed, at  rst there were con icting views as to the very 
existence of this pigment in the living eye, with numerous 
authors, including Home 2 and Gullstrand 3 believing it to be 
a post-mortem artifact.
It has long been recognised that MP preferentially absorbs 
short wavelength light prior to photoreceptor stimulation, 
and the hypothesis that filtering such defocused short 
wavelength light could enhance visual performance by 
reducing the effects of chromatic aberration goes back as 
far as Schültze 4 in 1866. This hypothesis, especially in 
relation to MP, remains unproven and poorly investigated. In 
this review, we explore the contribution of MP to visual 
performance and experience, and report and critically 
appraise the evidence in support of the notion that MP is 
important for vision.
The selective accumulation at the macula of only three 
dietary carotenoids, to the exclusion of the other forty dietary 
carotenoids, suggests an exquisite biological selectivity for 
lutein (L), zeaxanthin (Z) and meso-zeaxanthin (meso-Z) at 
the site of maximum visual acuity in the human retina, and 
also suggests a specific role for these carotenoids which is 
uniquely suited to this anatomic location. Given that Darwinian 
natural selection is based on the premise that phenotypic 
expression of genetic background confers advantage before 
and until the period of procreation, it is reasonable to infer 
that the biological selectivity of MP’s accumulation in the 
retina is advantageous in young and middle age.
MP may protect against the development of age-related 
macular degeneration (AMD) by defending the retina against 
cumulative and chronic (photo)-oxidative damage. It is likely, 
however, that the primary role of MP rests on its contribution 
to visual performance and experience, although the pigment 
may also longitudinally contribute to the preservation of 
macular function by preventing or delaying the onset of 
retinal disease such as AMD through its protection against 
chronic (photo)-oxidative damage. In other words, and in 
theory at least, MP’s putative contribution to visual 
performance rests on its optical properties, whereas the 
putative protective effect of this pigment for AMD rests on 
its optical and/or its biochemical properties.
MP alters the spectral composition of the light incident 
upon macular photoreceptors, but whether such short 
wavelength absorption in uences the quality of the visual 
experience, and whether the magnitude of any such effect 
correlates with MP optical density (MPOD), are questions 
that remain unanswered. Meaningful comment on the 
contribution of MP, if any, to visual performance must 
(1) consider the primary factors that affect visual perfor-
mance, (2) outline the properties of MP that make it 
potentially important for visual performance in light of any 
such limiting factors, (3) critically appraise the current 
literature germane to the role of MP in visual performance 
and experience and (4) suggest experimental strategies 
designed to investigate whether MP is important for visual 
performance and experience.
Visual performance
Current and unifying concepts
Snellen was the  rst to standardise the measurement of visual 
acuity with his letter chart, a chart design, which despite 
numerous limitations, remains the most widely used means of 
quantifying visual performance in the clinical setting. There 
remains, however, a myriad of other independent and/or 
overlapping techniques by which one can measure visual 
performance and experience across a range of functional 
levels.
Vision includes the capacity to detect objects against a 
contrasting background, to detect gaps between objects, to 
perceive subtle vernier offsets (which provides one example of 
hyperacuity), to recognise and identify objects, to perceive 
colour, to detect movement, and to perceive depth, amongst 
other faculties. It is important to note that the capacity to 
recognise a small distant object bears little relation to the 
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capacity to differentiate colours, or to detect a potential threat 
such as an oncoming vehicle in the peripheral  eld of view.
Visual performance is critically dependent on illumination, 
and the range of illumination we experience in the course of 
a typical day is vast. The visual system copes with such 
changes in illumination by adapting to the prevailing 
conditions, and can function through an approximate 8 log 
unit luminance range. Although adaptation facilitates 
performance over a wide range of ambient illumination 
levels, it does not follow that we see equally well at all levels. 
Under dim conditions, for example, the visual system is very 
sensitive and can detect subtle changes in luminance, but 
acuity for pattern details and colour discrimination is poor.
Shlaer 5 has explored the relationship between illumination 
and visual acuity (Figure 1). Converting his  ndings to Snellen 
equivalent, daylight (photopic) performance of 20/10 reduces 
to 20/600 under dim conditions, a 60-fold reduction. Threshold 
visibility, colour appearance and visual acuity all vary 
dramatically with illumination, and these visual parameters 
change over the time-course of light and dark adaptation. 
Therefore, and by de nition, no single test or testing condition 
can be used to investigate visual performance, and no single 
test can predict performance on other tests.
Further, any discussion of the visual processes must include 
those mechanisms contributing to perception. The visual 
system employs numerous anatomic and physiological 
strategies, including lateral interactions between cells, speci c 
receptive  eld organisation, spatial retinotopic organisation in 
retinal and non-retinal areas of the pathway, colour opponency 
and parallel visual pathways, amongst others, in order to 
achieve an instantaneous, coherent and highly detailed 
perception of the outside world and our position within it. Such 
image processing is not exclusive to the brain, but extends 
throughout the visual pathway beginning at the retina.
The eyes and brain are thus inextricably linked with the 
visual universe. The eyes actively record the form, colour 
and movements of the world, and the brain moulds these 
raw perceptions into recognisable patterns. The retina 
essentially acts as a spatial, temporal and spectral  lter of 
patterns of light striking its surface. Its anatomic structure 
and the functional properties of individual cells determine 
the type of information extracted from a visual scene and 
delivered to the brain.
Specialisation of the maculas
The macula, which comprises less than 4 % of the total retinal 
area, subserves almost all of our useful photopic vision. 
Several distinctive anatomic and neural adaptations facilitate 
such a high level of visual performance. These include:
1.  Cone density peaks at the centre of the macula (fovea), 
which intersects the line of sight. Cones here are smaller, 
more densely packed and more numerous than elsewhere 
in the retina, thus extending the limits of spatial acuity. 
Cone density exceeds rod density only at the lower part 
of the foveal slope, reaching a maximum at the base of 
the fovea (foveola) where cone density is over three 
times that observed at the foot of the foveal slope. 6 
Rods, ganglion cells and all inner nuclear layer neurons 
are absent from the foveola, so that only here is light 
directly incident on photoreceptors (elsewhere light 
must traverse the various retinal cells and layers to reach 
photoreceptors). It is also worth noting that short wave-
length sensitive cones are absent at the foveola.
2.  Midget pathways arising from these foveal cones domina-
te. Such parvocellular midget pathways are tuned to high 
spatial frequencies and also exhibit colour opponency.
3.  Such midget pathways are distinctive because of the 
absence of convergence of photoreceptor signals onto 
bipolar and ganglion cells. Absent or reduced convergence 
of information preserves the data gathered at the fovea 
for delivery to the visual cortex. Such differences 
between foveal and extra-foveal pathways generate a 
hierarchy in the processing of information gathered by 
the retina.
Retinal hierarchy
Anatomic and physiological observations, such as the 
differential light sensitivity of photoreceptors, the variable 
density and distribution of photoreceptors and ganglion cells 
across the retina and the convergence of information from 
the extra-foveal retina, means that a hierarchy exists in the 
architecture of retinal processing, where foveal information 
is given higher priority. This hierarchy is preserved to the 
striate cortex, where a high percentage of cortical cells are 
dedicated to information of foveal origin. The central retinal 
pathways have by far the greatest proportion of representation 
(estimates range from 25 % of the cortex devoted to the 
central 5 degrees, 37 % devoted to the central 15 degrees 7 
and 87 % of the cortex devoted to the central 30 degrees of 
visual  eld 8).
Having outlined those anatomic and neural factors central 
to primates’ capacity for high acuity vision, it is now 
important to consider the potential role of MP in visual 
performance. In order to do so, it is essential to characterise 
(a) the optical limitations that might restrict visual 
performance (in particular chromatic aberration and light 
scatter) and (b) the properties of MP that might serve to 
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Figure 1 Relationship between visual performance (as log 
visual acuity) and retinal illuminance. As retinal illuminance 
increases, visual acuity increases by up to 2 log units (cone-
mediated improvements account for the most significant 
improvements from approximately 6/60 to 6/3 Snellen equiva-
lent-see upper portion of curve). Shlaer 5.
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lessen the effect of such limitations, and thereby facilitate 
optimal visual performance.
Optical limitations of the eye
Monochromatic aberrations and diffraction limit the image 
quality produced by the eye, so that the image is not always 
a high quality representation of the object. While there is 
signi cant ocular and neural correction for, and adaptation 
to, such image defects, MP most likely has no role in altering 
their effects (although Kvansakul et al. 9 have noted some 
surprising observations of a trend towards lower root mean 
square wavefront aberrations in a small group of subjects 
following supplementation with L and Z, which, they 
postulate, may be as a result of the as yet unknown effects 
of carotenoid intake on crystalline lens function).
Chromatic aberration
Chromatic aberration, comprising both longitudinal (LCA) 
and transverse (TCA) components, has been cited as possibly 
the most significant aberration affecting visual quality. 10 
Indeed, LCA creates up to two dioptres of wavelength-
dependent optical defocus. Campbell and Gubbisch 11 have 
demonstrated improvements in contrast thresholds of up to 
65 % at intermediate spatial frequencies once monochromatic 
yellow light is employed in place of spectrally broadband 
white light. Although Bradley 12 later modelled the effects of 
chromatic aberration, and concluded that the effect of 
chromatic aberration on the modulation transfer function 
was small, and equivalent to approximately 0.15D of defocus, 
upper resolution limits of the visual system however, are 
most likely de ned by the effects of chromatic aberration. 13
The effect of LCA across wavelength, in terms of blur, is 
non-linear, as shorter wavelengths are signi cantly more 
defocused than longer wavelengths. For example, an eye 
focussed at 550 nm, light at 460 nm suffers 1.2D myopic 
defocus, while the equivalent long wavelength of 640 nm is 
only 0.50D out of focus. 10 This serves to create a purple blur 
circle haze around the focussed “green” component. 
Figure 2 demonstrates the non-linearity of defocus and the 
relative luminance pro le across wavelength. As the spectral 
extremities have less luminosity, the effects of chromatic 
aberration on image focus are mitigated in terms of the 
effects on vision. Mitigation is potentially further aided by 
the fact that blue light is selectively absorbed by MP.
Light scatter
If one looks up to the sky on a bright, cloudless sunny day, 
one could be fooled into thinking that the sun’s rays traverse 
an unobstructed path to the eye. Furthermore, one could 
certainly not imagine that the quality of the light visible 
was being degraded as it traversed the seemingly clear sky, 
even in the most remote countryside locations far from the 
smog- lled cityscapes, on its way to the eye. The fact that 
the sky is blue is testament to the impact of the process of 
light scatter, whereby particle matter abstracts and 
re-radiates energy from light incident upon it.
A multitude of visible and non-visible particles, varying in 
size from atmospheric oxygen and nitrogen, to haze 
aerosols, to larger complexes such as fog, cloud and rain, all 
contribute to such scatter. Wooten & Hammond, 14 in an 
excellent review of the importance of light scatter to the 
“visibility” of objects, eloquently describe why light scatter, 
especially that induced by haze aerosols “critically 
determines how far one can see and how well details can be 
resolved”, so that, aside from the optical and neural limits, 
“scatter in the aerosol haze is the primary determinant of 
visual discrimination and range in the outdoors”.
The question therefore arises, what effect does light 
scatter have on visual performance? And it is a good question. 
On a clear day one can see for miles despite the effects of 
scatter. Wooten & Hammond, 14 however, propose a model 
whereby compensation for the effects of light scatter, such 
as could reasonably be achieved by increasing the optical 
density of MP, would increase the visibility and discriminability 
of targets in natural settings. In their model, a 1 log unit 
increase in MPOD attenuates the veiling luminance of the 
short-wave dominant background by 26 % (or 17 % for a more 
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practical 0.5 log unit increase in MPOD), while having 
minimal effect on the short wave de cient distant target. 
The attenuation of the effects of light scatter is thereby 
observed to enhance target detection and discrimination 
capacity, and extend the visual range by up to 18.6 %.
Tackling the question from another perspective, the 
problems caused by scatter, while not consciously 
experienced by most people, do become a significant 
symptom of which many patients complain in the form of 
discomfort and disability glare. Aside from patients without 
detectable ocular abnormality, typical patients with 
such symptoms include those with cataract, corneal 
abnormalities, intraocular in ammation, and following laser 
refractive surgery, amongst others. Therefore, scatter does 
have an adverse effect on the visual experience of normal 
subjects and on those with ocular pathology, and any means 
of alleviating such effects would be of clinical importance.
The possible effect of aberrations such as LCA, and also of 
short wavelength light scatter, is that capacity limits are 
somewhat reduced so that the anatomic limits of acuity 
based on foveal cone diameter (30 seconds arc — equivalent 
to 6/3) are seldom achieved, even in healthy normal 
individuals, with the exception of hyperacuity tasks which 
have different underlying neural bases.
So the question arises, what are the properties of MP that 
might allow it to improve visual performance in light of the 
limiting factors outlined above?
Optical and anatomic properties of MP
MP’s optical and anatomic properties have prompted the 
“optical” hypothesis of this pigment, which has been discussed 
in detail by Reading & Weale 15 and later by Nussbaum et al. 16 
The optical effect of MP is somewhat evidenced by two 
entoptic phenomena known to exist which are speci c to the 
macula, namely Maxwell’s spot and Haidinger’s brushes. 16 The 
former,  rst described in 1844, is attributed directly to the 
deposition of pigments at the macula and results in a dark red 
spot being visible around the fixation point if a brightly 
illuminated white surface is viewed alternately through purple 
and neutral  lters. Magnussen et al. 17 have shown that the 
absence of short-wave-sensitive cones in the human foveola, 
which normally goes unnoticed unless a subject’s  eld of view 
is restricted to the foveola, producing the artificial colour 
vision defect of foveal tritanopia, 18,19 results in a blue scotoma 
which can be visualised as the negative afterimage of a 
short-wavelength adapting  eld on a larger white background. 
The afterimage has an annular shape with a lighter inner 
region that corresponds to Maxwell’s spot, and a small bright 
spot in the centre, corresponding to the foveal blue scotoma. 
The MP distribution measured for the same observers closely 
corresponded to the lighter annular region of the afterimage.
Haidinger’s brushes, first reported in 1844, refers to a 
propeller-shaped image which is seen most clearly through a 
rotating  lter producing plane-polarised light. It is known 
that lutein has dichroic properties 20,21 and it has been shown 
that bovine lutein and zeaxanthin bind to bovine retinal 
tubulin. 22 It is thus possible that dichroic macular pigments 
are laid down in a highly organised manner following the 
radial arrangement of Henle’s fibres at the macula, thus 
explaining the shape and brush-like appearance of the 
propeller-like images. 23
However, it should be noted that neither of these entoptic 
phenomena is visible in normal viewing conditions, probably 
because of adaptatory effects, particularly at the level of 
the visual cortex. It is uncertain whether the concentration 
of MP has any significant influence on vision under such 
conditions.
MP may be important for visual performance and/or 
experience however by at least one of the following 
mechanisms (summarised by Walls & Judd 24): MP may enhance 
visual acuity by reducing chromatic aberration (effects); MP 
may reduce visual discomfort by attenuation of glare and 
dazzle; MP may facilitate enhancement of detail and visual 
contrast by the absorption of “blue haze”. MP has the capacity 
to achieve the above optical effects because of its optical 
properties and because of its location within the retina.
The term macula lutea is actually attributable to the 
presence of the xanthophyll pigments, L, Z, and meso-Z at 
the central region of the retina, which give rise to the 
appearance of a yellow spot (macula lutea) when viewed 
under red-free light (Figure 3). The yellow coloration of MP 
is such that it selectively absorbs blue-green incident light, 
Figure 3 Histological section illustrating the spatial pro le 
and pre-receptorial location of MP, the main location of macular 
pigment was in the layer of the  bres of Henle in the fovea (a) 
and in the inner nuclear layer at the parafoveal site (b).
Reprinted with permission: Trieschmann et al., 2008 78
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with maximum absorption circa 460 nm and little or no 
absorption above 530 nm. 25 Given that (1) the peak retinal 
spectral sensitivity lies at 555 nm, (2) the proportion of blue 
(short wavelength sensitive) cones in the central macula is 
far lower than that of red (long wavelength sensitive) and 
green (medium wavelength sensitive) cones and (3) the 
region of maximal visual performance, the foveola, is 
essentially devoid of short wavelength sensitive cones, it 
would appear that the optical properties of MP are such that 
it attenuates the component of light that is least bene cial, 
and most deleterious, with respect to visual performance 
and experience. As Wald 26 summarised, the various adaptive 
mechanisms in the human eye serve to “withdraw vision 
from the blue” end of the spectrum.
Two aspects of MP’s location within the retina are also 
central to the hypothesis that it has a role to play in visual 
performance. Firstly, although MP is found throughout the 
retina and other ocular structures, 27 it reaches its greatest 
concentration at the macula, and remains optically 
undetectable elsewhere. Secondly, and importantly, MP is 
located at a pre-receptoral level, so that absorption of short 
wavelength light occurs prior to stimulation of the underlying 
photoreceptors, thereby altering the spectral distribution of 
light incident on such photoreceptors in a favourable way 
(Figure 3).
Short wavelength light absorption attenuates the more 
disadvantageous component of LCA. Retinal image quality is 
thereby improved, and visual performance across the full 
contrast range is theoretically more refined. As MP 
absorption overlaps with that of rhodopsin, MP may reduce 
rod signal effectiveness in the mesopic range, and thus 
extend the usefulness of cone-mediated vision into the 
mesopic range. 9 In addition, short wavelength light absorp-
tion has the bene t of improving target contrast by selec-
tively reducing the scattered short wavelength light in the 
background. Reduced LCA and reduced scatter effects, 
resulting from MP’s absorptive characteristics, have the 
potential to improve visual acuity and target visibility, and 
perhaps in an interactively additive fashion. 14
The higher energy and retinal irradiance associated with 
shorter wavelengths (International Commission on 
Non-Ionizing Radiation Protection, 1997 28) also merits 
consideration. Bright light, which interferes with the quality 
of visual perception, is termed glare, of which there are 
numerous types. In high luminance or high contrast situa-
tions, where glare and dazzle are maximal, MP absorption of 
short wavelength light attenuates the highest energy light 
component, and reduces retinal irradiance, and therefore 
may minimise the impact of glare on performance, and 
increa se the threshold for photophobia under normal 
viewing conditions. Because of their linear structure, L, Z, 
and meso-Z also exhibit dichroic properties, 29 which 
facilitate glare reduction by preferential absorption of 
polarised light. Glare symptoms remain a common and 
important clinical entity in optometric and ophthalmological 
practice, and very troublesome for those who experience 
it. 30 Furthermore, symptoms of glare remain difficult to 
quantify and treat. Interestingly, difficulty with glare is 
often one of the earliest manifestations of AMD.
It should now be clear, because visual performance is a 
complex subject, which is difficult to quantify, and 
dependent on numerous independent and overlapping 
variables, that to investigate the contribution of any one 
factor (such as MP) presents numerous challenges. It is with 
this thought in mind that currently available evidence on 
the impact of MP on visual performance and experience will 
now be explored.
Evidence that MP plays a role 
in visual performance and experience
Background
The evidence in relation to a role for MP in visual 
performance is sparse and is largely associative. To our 
knowledge, there are no published studies which have 
satisfactorily investigated the hypothesis that MP in uences 
visual performance and experience. However there are 
numerous and con icting reports on the effect of yellow 
filters on visual performance, 31 but none of these have 
included measures of MPOD. Failure to do so confounds any 
reasonable interpretation of short wavelength light 
absorption effects on visual performance, as variations in 
MPOD between and within study populations could account 
for the reported observations.
There are thus two strategies to investigate the impact 
of MP on visual performance. The first is to quantify 
performance using a range of functional tests, and to 
correlate the results with measures of MPOD. Given the 
other variables involved in vision, the true effect of MP 
would, in our opinion, prove dif cult to isolate with such a 
paradigm. The alternative and most appropriate means to 
investigate the effect of MP is to measure baseline visual 
performance, as above, and to record baseline MPOD, and 
then repeat functional vision tests during an extended 
period of supplementation with MP xanthophylls. If MP 
in uences visual performance it must do so either as (1) a 
filter or (2) through some biological mechanism. With 
respect to the former (1), any effects on visual performance 
should follow the known absorbance characteristics of the 
pigments. Hence, the visual stimuli to be used to 
investigate the role of MP should have signi cant amounts 
of short wave energy, in order to replicate the effects of 
ecologically valid stimuli (e.g. the sun) which have lots of 
short wave energy. Biological effects (2) would likely be 
based on either enhanced protection (healthier retinas and 
crystalline lenses would lead to better vision, especially in 
the elderly) or effects throughout the visual system. If MP 
has a role, and its contribution is related to either its 
optical density and spectral absorbance characteristics, or 
to possible biological effects on retinal, crystalline lens 
and visual system health, then increasing MPOD through 
supplementation should result in improved performance 
and experience. The key then is to accurately detect and 
quantify any such changes through a comprehensive 
battery of appropriate tests that analyse vision on a 
number of functional levels, including basic acuity, contrast 
sensitivity across illumination levels, colour perception, 
and glare sensitivity, amongst others.
Those studies that have addressed visual performance are 
largely con ned to populations with established eye disease 
(summarised in Table 1), and therefore the results should be 
interpreted with full appreciation of the fact that the  ndings 
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do not necessarily hold true for subjects without retinal 
pathology. Studies involving normal subjects will therefore be 
reviewed separately here (summarised in Table 2).
Studies in subjects with retinal pathology
Hereditary retinal degenerations
Abnormal light sensitivity, dif culty associated with glare, 
loss of contrast and slow dark adaptation are symptoms 
commonly reported by patients with hereditary retinal 
degenerations. It is possible that such symptoms could be 
attributable, at least in part, to the failure of MP to absorb 
scattered light, resulting in reduced contrast and de nition 
along with excessive photoreceptor pigment bleaching by 
short wavelength light components.
The antioxidant and absorptive properties of MP would 
therefore suggest a potentially useful role for the macular 
carotenoids in retinal degenerations, where the clinical aim 
includes optimisation of current visual status in the short 
term and preservation of macular vision in the long term. 
Indeed, it is noteworthy that there have been reports (some 
dating back > 50 years) suggesting that patients with retinitis 
pigmentosa (RP) demonstrated improvements in visual 
performance following supplementation with lutein-containing 
compounds (reviewed elsewhere 16).
Dagnelie et al. 32 assessed the effect of L supplementation 
in patients with RP, and reported moderate visual 
improvements following short-term supplementation with 
L. Mean visual acuity improved by 0.7 dB and mean 
visual-field area by 0.35 dB, although the largest gains 
Table 1 Publications exploring the relationship between macular pigment and visual performance and experience 
in subjects with ocular disease
Study (author, year) Subjects (n) Supplement (dose per/day & time)  
CROSS SECTIONAL STUDIES
Hammond et al., 1997 Cataract None
Brown et al, 1999 Cataract None
Chasan-Taber et al., 1999 Cataract None
Schupp et al., 2004 Cystic  brosis (10) None
INTERVENTION (SUPPLEMENTATION) STUDIES
Andreani & Volpi, 1956a Retinitis pigmentosa (8) Lutein dipalmitate
Mosci, 1956a Retinitis pigmentosa Lutein dipalmitate
Cuccagna, 1956a Myopia & RP Lutein dipalmitate
Pfeiffer, 1957a Abnormal dark adaptation (13) Lutein dipalmitate
Hayano, 1959a Retinitis pigmentosa Lutein dipalmitate
Muller-Limroth & Kuper, 1961a Retinitis pigmentosa (18) Lutein dipalmitate
Asciano & Bellizzi, 1974a Progressive myopia with 
chorio-retinal atrophy (50)
Lutein dipalmitate
Richer, 1999 AMD (14) 10mg lutein (5 ounces spinach 4 times per week)
Dagnelie et al., 2000 Retinitis pigmentosa (16) 40 mg lutein (2 months) followed by 20 mg (4 months)
Aleman et al., 2001 Retinitis pigmentosa (47) 
 & Usher syndrome (11)
20 mg lutein (6 months)
Duncan et al., 2002 Choroideremia (13) 20 mg lutein (6 months)
Falsini et al., 2003 AMD (30) 17 subjects took 15 mg/L + 20 mg vitamin 
 E + 18 mg nicotinamide (6 months); 
 13 subjects had no supplementation
Olmedilla et al., 2003 Cataract (17) 15 mg lutein or 100 mg a-tocopherol or placebo 
 3 times per week
Richer et al., 2004 AMD (90) 10 mg/L or 10mg/L + antioxidants or placebo (1 year)
Bartlett & Eperjesi, 
 2007
ARM & AMD (25) 6 mg lutein + vitamins A,C + E + zinc + copper
Aleman et al., 2007 Stargardts’ disease or 
 cone-rod dystrophy (17)
20 mg/L (6 months)
Parisi et al., 2008 Early AMD Vitamin C & E, Zinc, Copper, 10 mg lutein, 
 1 mg zeaxanthin,  4 mg Astaxanthin (12 months)
AMD indicates age-related macular degeneration; ARM, age-related maculopathy; MPOD, macular pigment optical density.
aData from Nussbaum, 1981.
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were observed in blue-eyed participants. Aleman et al. 33 
explored the relationship between visual function and L 
supplementation in RP patients over a six month period, 
and despite increases in MPOD, could  nd no signi cant 
improvement in visual performance (measured as absolute 
foveal sensitivity). The dosage used in this latter study was 
lower than that in the Dagnelie report, which may explain 
the discrepancy in the findings of these two studies. 
Neither study, however, analysed visual function in 
suf cient detail or followed patients for suf cient time to 
make meaningful comment on whether the natural history 
of RP is modi ed following supplementation with L.
Duncan et al. 34 analysed MP levels and macular function in 
choroideremia (a progressive degeneration of photo-
receptors, RPE and choroid). Once again, and in spite of 
augmented MPOD following supplementation, no improve-
ment in retinal sensitivity was observed.
Aleman et al. 35 measured MPOD in patients with 
Stargardt’s disease or cone-rod dystrophy with known or 
suspected disease-causing mutations in the ABCA4 gene, 
and investigated response to supplemental L in terms of 
changes in MPOD and central visual function. They reported 
that MPOD is inversely related to the stage of ABCA4 disease 
at baseline, and could be augmented by supplemental L in 
about two thirds of patients. However, measures of visual 
function, including visual acuity and foveal sensitivity, 
exhibited no discernable improvement after 6 months of 
supplementation. They concluded that the long-term 
in uences of L supplementation on the natural history of 
such macular degenerations require further study.
 Outcome measure Findings
Crystalline lens transparency versus MPOD Higher MPOD correlated with a more transparent crystalline lens
Incidence of cataract versus MPOD Higher MPOD correlates with decreased cataract formation
Incidence of cataract versus MPOD Higher MPOD correlates with decreased cataract formation
Contrast sensitivity, colour discrimination 
 & erg amplitude
No statistical difference between CF and normals although normals 
 had marginally better performance
Dark adaptation Primary & secondary portions of DA curve improved
Light sensitivity Sensitivity improved
Dark adaptation DA improved
Dark adaptation Only marginal improvements observed, but used smaller doses than others
Dark adaptation DA improved proportional to the increase in blood lutein
ERG potentials No change
Light & chromatic sensitivity Sensitivity on both measures improved
Contrast sensitivity 92 % showed improvements in contrast sensitivity
Visual acuity and visual  eld VA improved 0.7 dB, visual  eld area increased by 0.35 dB, largest gains 
 in blue eyes
Foveal sensitivity No improvement – lower dose than Dagnelie study, MP density may be 
 affected by stage of retinal disease
Foveal sensitivity (dark adapted) No improvement
Focal Electroretinogram (ERG) amplitude Signi cant improvement, MPOD not recorded
Visual acuity & glare sensitivity Improvements in both measures, no change in placebo group 
 or a-tocopherol group
Visual Acuity & CSF & Amsler Signi cant improvement in both groups L = 5.4 letter increase, 
 L + antioxidants = 3.5 letter increase; no effect on contrast sensitivity; 
 improved performance on amsler grid
Contrast sensitivity No improvement in performance
Visual acuity and foveal sensitivity No improvement with increased L, MPOD was inversely related to stage 
 of disease
Multifocal ERG Response Amplitude Density (RAD) Central (5 deg) RAD reduced at baseline in AMD compared with 
 healthy controls, Central (5 deg) RAD improved signi cantly 
 in the supplemented group, MPOD not recorded
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Age-related macular degeneration
AMD, as the leading cause of blindness in the western world, 
is the most commonly investigated retinal condition with 
respect to the potential bene ts of supplemental L, Z, or 
meso-Z. Observations, including relative preservation of 
short wave sensitive cones centrally when compared to the 
perifoveal region 36 and the initiation of geographic atrophy 
in the perifovea, where MPOD is lowest, are consistent with 
the view that MP protects against AMD and against 
psychophysical changes known to precede this condition. 
Since publication of the findings of the Eye Disease 
Case-Control Study Group, where a 60 % risk reduction for 
AMD in association with a high dietary intake of L and Z was 
reported, 37 numerous investigators have further explored 
the relationship between dietary and serum levels of MP’s 
constituent carotenoids and risk for AMD. 38 With a couple of 
exceptions (outlined below), studies investigating serum 
levels of, dietary intake of, or supplementation with, L 
and/or Z with respect to risk for AMD and/or its progression 
have (understandably) considered preservation, rather than 
enhancement, of visual performance, to represent the most 
appropriate outcome measure (reviewed elsewhere 39).
Richer 40 evaluated the effect of dietary modi cation on 
visual performance for patients with atrophic AMD. 
Fourteen male patients (70 ± 9 years), receiving 
0.73 ± 0.45 portions of dark-green, leafy vegetables/day 
base intake, were placed on an additional portion of 
5 ounces sautéed spinach 4 to 7 times per week or lutein-
based antioxidant (3 subjects). Patients demonstrated 
short-term enhancement of visual function in one or both 
eyes in terms of amsler grid testing, Snellen acuity, 
contrast sensitivity, glare recovery, and subjectively on the 
Activities of Daily Vision Subscale. The authors concluded 
that the effect of dietary modification on the natural 
course of atrophic AMD warranted investigation in the 
context of a randomised, controlled trial.
Such an evaluation was conducted in the LAST (Lutein 
Antioxidant Supplementation Trial) study. Richer et al. 41 
evaluated the effect of supplementation on visual 
performance in atrophic AMD on 90 subjects in a double 
blind, placebo controlled trial. Average MPOD increased by 
0.09 log units (or 50 %) after 12 months, in the L and L plus 
antioxidant groups. The investigators observed concurrent 
and statistically significant improvements in contrast 
sensitivity, visual acuity and subjective measures of glare 
recovery in both treatment groups, but not in the control 
group. Snellen-equivalent acuity improved by 5.4 letters in 
patients supplemented with L, and by 3.5 letters in patients 
supplemented with L plus antioxidants, whereas 
improvements in contrast sensitivity were significantly 
better in the L plus antioxidant group than in the L group.
Falsini et al. 42 studied the effect of supplemental L on 
central retinal function, assessed electrophysiologically, in 
patients with early AMD, and reported a significant 
Table 2 Publications exploring the relationship between macular pigment and visual performance and experience in normal 
subjects
Study (author, year) Subjects (n) Supplement (dose & time)  
CROSS SECTIONAL STUDIES
Hammond et al., 1998 Normals None
Stringham et al., 2003 Normals None
Stringham et al., 2003 Young normals (16) None
Stringham & Hammond, 2007 Normals (36) None
Engles et al., 2007 Normals (80) None
INTERVENTION (SUPPLEMENTATION) STUDIES
Monje, 1948a Normals (14) Lutein dipalmitate (2-6 months)
Wustenberg, 1951a Normals (7) Lutein dipalmitate
Klaes & Riegel, 1951a Normals Lutein dipalmitate
Andreani & Volpi, 1956 Normals (10) Lutein dipalmitate
Mosci, 1956a Normals Lutein dipalmitate
Hayano, 1959a Normals Lutein dipalmitate
Wenzel et al., 2006 Normals: No supplement (6); 
 supplement (4)
30 mg lutein + 2.7 mg zeaxanthin (12 weeks)
Rodriguez-Carmona et al., 
 2006
Normal trichromats (24) 10 mg (6 months) + 20 mg (6 months) of lutein or zeaxanthin, 
 10 mg lutein + 10 mg zeaxanthin or placebo
Kvansakul et al., 2006 Normals (34) 10 mg lutein, 10 mg zeaxanthin, 10 + 10 mg combination 
 or placebo (6 months)
Bartlett & Eperjesi, 2008 Normals (46) 6 mg lutein + vitamins A, C, E + zinc + copper
Stringham & Hammond, 2008 Normals (40) 10 mg lutein + 2 mg zeaxanthin (6 months)
MPOD indicates macular pigment optical density.
aData from Nussbaum, 1981.
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improvement in focal ERG amplitude after six months of 
supplementation, and this was followed by regression back 
to baseline values following discontinuation of the 
supplement. Unfortunately, the investigators did not 
measure MPOD, and therefore conclusions must be 
interpreted with full appreciation of this limitation.
Bartlett and Eperjesi 43 undertook a prospective, 9-month, 
double-masked randomised controlled trial of the effect of 
supplementation with lutein combined with vitamins and 
minerals on contrast sensitivity among participants with age 
related maculopathy and atrophic AMD. Contrast sensitivity 
was assessed using a Pelli-Robson chart and participants 
were randomised into active and placebo treatment groups. 
The authors report no signi cant improvement in contrast 
sensit ivity among either group and suggest that 
supplementation with 6 mg/L and other antioxidant vitamins 
and minerals has no tangible bene t to this group (although 
one could argue that preservation rather than enhancement 
of performance might be a more suitable outcome measure 
for AMD patients) and further, that determination of 
optimum dosage levels requires further work. Their  ndings 
are naturally con ned to the somewhat limited measure of 
contrast sensitivity with a Pelli-Robson chart that may not 
be best equipped to detect subtle changes in performance. 
Failure to record MPOD at baseline, and the low dosage of 
supplemental L, represent design  aws in that study, and 
limit the scope for meaningful comment. Parisi et al. 44 have 
also recently explored the in uence of short-term carotenoid 
and antioxidant supplementation on electrophysiologically 
assessed retinal function in early AMD. Of the 27 early AMD 
patients enrolled in their study, 15 had daily oral 
supplementation of vitamin C (180 mg), vitamin E (30 mg), 
zinc (22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin 
(1 mg), and astaxanthin (4 mg) for 12 months, while the 
remaining 12 had no dietary supplementation during the 
same period. Fifteen age-similar healthy controls were also 
assessed at baseline and followed-up for the duration of the 
study period without supplementation. Multifocal 
electroretinograms, in response to 61 M-stimuli presented 
to the central 20 degrees of the visual  eld (averaged across 
5 retinal eccentricity areas between the fovea and 
mid-periphery: 0 degrees to 2.5 degrees, 2.5 degrees to 
5 degrees, 5 degrees to 10 degrees, 10 degrees to 15 degrees, 
and 15 degrees to 20 degrees) were assessed at baseline in 
controls and in early AMD patients, and again at 6 months 
and 12 months. At baseline, they observed highly signi cant 
reductions of N1-P1 response amplitude densities (RADs) for 
the central five degrees surrounding the fovea in AMD 
patients when compared with healthy controls. For more 
peripheral retinal eccentricities, RADs were not signi cantly 
different from controls. After 6 and 12 months of treatment, 
the treated group showed highly significant increases in 
N1-P1 RADs for the two most central retinal areas, but not 
for more peripheral eccentricities beyond 5 degrees. The 
 Outcome measure Findings
Scotopic sensitivity & short wave sensitivity Higher MPOD associated sensitivities equivalent to younger observers
Photophobia Higher MPOD correlated with less photophobia
Short wave increment thresholds No correlation with MPOD
Photostress recovery and grating visibility Higher MPOD relates to shorter recovery times and improved sensitivity
Gap acuity and vernier acuity No correlation with MPOD
Dark adaptation & scotopic visual acuity Both dark adaptation and scotopic visual acuity showed transient 
 improvements
Dark adaptation No improvement but experimental error has been suggested
Dark adaptation Dark adaptation improvement lasting up to 4 months
Dark adaptation Primary & secondary portions of dark adaptation curve improved
Light sensitivity Sensitivity improved
Dark adaptation Dark adaptation improvements proportional to blood lutein increase
Photophobia MPOD correlated with baseline sensitivity and improved with 
supplementation
Blue/yellow colour discrimination No effect of supplementation on colour discrimination
Mesopic contrast acuity Supplementation improved performance with lutein, zeaxanthin 
 or combination, no improvement with placebo
Visual acuity (near + distance), contrast sensitivity 
 and photostress recovery
No performance improvement over 9 months or 18 months
Photostress recovery and grating visibility Increased MPOD led to improved performance and faster recovery
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non-treated control group exhibited no significant RAD 
changes at any eccentricity. These  ndings suggest that in 
early AMD eyes, central retinal function (0 degrees 
–5 degrees) can be improved by supplementation with 
carotenoids and co-antioxidants. The study design, however, 
does not clarify whether such improvements in retinal 
function have a measurable impact on visual performance 
and experience, and the failure to measure and record 
MPOD somewhat limits the interpretation of these 
potentially important  ndings.
Cataract
Olmedilla et al. 45 investigated whether supplemental L 
influences visual function in patients with age-related 
cataract, where visual performance was evaluated by 
measures of visual acuity and glare sensitivity. This 
randomised, placebo-controlled trial revealed signi cant 
improvements in visual acuity and glare sensitivity following 
supplemental L, and the observed improvements were 
related to changes in serum levels of L, whereas no such 
improvements were observed in patients supplemented with 
placebo or with a-tocopherol. While contrast sensitivity was 
not recorded at baseline or during the supplementation 
phase, it is interesting to note that in cataract patients 
supplemented with lutein, contrast sensitivity at the end of 
the supplementation period was similar to or even better 
than that expected for control subjects of a similar age. The 
authors postulated that the observed improvements in the 
outcome measures were not the result of any change in the 
crystalline lens, but more likely to be the result of improved 
retinal function.
Studies in normal populations
Photophobia and glare
Photophobia is a phenomenon experienced by all persons 
when illumination is suddenly and dramatically changed 
from dark to light, and is typified by the experience of 
switching on a bedroom light at night time. However, under 
normal daylight conditions, the experience of photophobia 
is somewhat more variable. Numerous clinical conditions 
(e.g. RP & AMD) are associated with photophobia, and, even 
in the absence of detectable disease, clinicians are often 
presented with patients whose primary complaint is of 
periodic or persistent sensitivity to bright light (but at levels 
which do not similarly affect colleagues/friends/family). 
Given its absorption characteristics, the optical density of 
MP may be important in determining an individual’s 
threshold for the subjective complaint of photophobia.
Stringham et al. 46 explored the effect of the spectral 
composition of a target on visual discomfort, using 
electromyography and a rating scale to determine 
photophobia thresholds. They showed that, while there was 
a positive relationship between wavelength and the energy 
needed to produce photophobia for wavelengths between 
520 and 640 nm, at shorter wavelengths there was a notch 
centred at 460 nm, the trough and shape of which resembled 
the log transmittance spectrum of MP. Their  ndings led the 
authors to suggest that MP may attenuate photophobia or 
visual discomfort induced by short wavelength sources.
These observations prompted a subsequent study 
investigating the relationship, if any, between MP and 
photophobia. 47 This two-part experiment explored the 
relat ionship between basel ine MPOD levels  and 
photophobia thresholds, as well as the effect of 
augmenting MPOD on such thresholds. Four subjects were 
supplemented with 30mg/L and 2.7 mg Z daily for 
12 weeks. Peak MPOD was observed to increase from 0.452 
(± 0.11) at baseline to 0.536 (± 0.11) at the end of the 
period of supplementation. A significant and inverse 
relationship between baseline MPOD and threshold for 
photophobia was observed, such that individuals with 
higher MPOD had higher tolerance for short wavelength 
light. Furthermore, increasing MPOD over a 12-week 
period appeared to increase the threshold for photophobia 
for all subjects for short wavelength sources.
Recently, Stringham & Hammond have explored the 
influence of glare on visual performance, and how MPOD 
might in uence any observed relationships. They  rst looked 
at baseline visual performance under glare conditions by 
evaluating photostress recovery (a sensitive indicator of 
macular function) and grating visibility. 48 The effect of 
veiling glare on grating visibility was explored using a  ve 
cycles per degree contrast grating stimulus, surrounded by a 
concentric annulus of adjustable intensity. For the 
photostress recovery test, the same stimulus was viewed 
following photostress with a 5 degree xenon white disc 
providing 5.5 log Trolands of retinal illuminance over 
5 seconds’ duration. MPOD was a signi cant determinant of 
the deleterious effects of glare, with visual thresholds and 
photostress recovery times significantly and inversely 
related to MPOD. Further, high MPOD was associated with 
better visual performance in a way that was consistent with 
its spectral absorbance and spatial pro le.
These observations prompted the same investigators to 
design and execute a trial of supplemental L (10 mg per day) 
and Z (2 mg per day), using the same testing conditions, but 
on this occasion looking for changes in performance 
associated with augmentation of MPOD. In this instance, 
they found that, following six months of supplementation, 
and an average increase in MPOD from 0.41 to 0.57, most 
subjects exhibited improved photostress recovery and glare 
tolerance in association with an increase in MPOD. More 
speci cally, a 39 % increase in MPOD enhanced tolerance of 
intense glaring light by up to 58 % and reduced photostress 
recovery times by 14 %. 49
Although the authors wisely suggest a cautionary approach 
to the interpretation of their data and the wider implications 
of such  ndings, their conclusion that the results are “both 
large enough and suf ciently general to be meaningful in 
real life”, and that “supplementing L and Z could indeed be 
palliative for those suffering the consequences of glare”, is 
important and warrants further investigation in the form of 
a randomised clinical trial.
Spatial vision
Engles et al. 50 have investigated the “acuity hypothesis”, 
exploring the relationship between MPOD and gap acuity 
and vernier acuity under “photopic” conditions. They report 
that neither gap acuity nor vernier acuity were signi cantly 
related with MPOD, and concluded that their “data suggest 
that the predictions of the acuity hypothesis do not hold”. 
While the authors qualify their  ndings as appropriate to 
their specific testing conditions alone, several study 
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limitations (other than those recognised by the authors) 
warrant brief discussion.
Firstly, although the authors report that their conclusions 
are relevant for photopic conditions, their adopted 
background luminance levels are in the low photopic range 
at best (17 cd/m 2 for the achromatic condition, and 
15.7 cd/m 2 for the chromatic condition), and certainly not 
appropriate for evaluation of photopic visual function. 
Indeed, given the subtle nature of any performance changes 
likely to be facilitated by MP, the background luminance 
difference (≈8 %) between the two testing conditions is also 
a potentially confounding factor.
Secondly, while all subjects were corrected to 6/6, it is 
plausible, indeed probable, that the actual acuity limits of 
their study population ranged widely between the 6/6 level 
employed up to a likely 6/3 limit for a young healthy 
subject. This potential two-fold range in acuity, subserved 
by individual optical, anatomic and neural architectures, 
would have a strong in uence on both gap and vernier acuity 
tasks, almost certainly more powerful than MPOD. Also, by 
adopting a 6/6 limit, the investigators most likely failed to 
correct for potentially signi cant amounts of uncorrected 
axial astigmatism in some subjects, which could signi cantly 
in uence performance on both of the chosen tasks (testing 
of vernier and gap acuity limits). While the authors could 
argue that any such variables remained consistent between 
testing conditions, we believe it would be more appropriate 
to eliminate sources of variability such as residual refractive 
error, so that all subjects operate at their limits of acuity.
The adoption of a single spatial frequency and contrast 
setting further limits the conclusions that can be drawn 
from this paper. The effect of MP, for example, might differ 
significantly under different spatial frequency and or 
contrast ranges. Assessment of visual performance across 
the full contrast sensitivity function might represent a more 
thorough and rigorous assessment of MP’s capacity to affect 
visual performance through attenuation of the effects of 
chromatic aberration and light scatter.
Finally, the subjects employed in the Engles study typically 
exhibited average to high MP levels, with few subjects 
exhibiting MP levels below 0.20. Reading and Weale 15 
previously modelled the potential effect on MP in terms of 
attenuation of the effects of chromatic aberration, and 
suggested that, due to the non-linear nature of the effect, 
MPOD levels above 0.30 were probably super uous. Based 
on the assumptions of this model, a study on the effect of 
MP on visual performance might require the inclusion of 
relatively more subjects that exhibit low MPOD levels in 
order to demonstrate an effect.
These limitations of the cited study serve to emphasize 
the challenges inherent in investigating the role of MP in 
visual performance and experience, which rest on the need 
(insofar as is possible) to disentangle the in uence of MP 
from the often unquantifiable and variable influences of 
individual optical and neural architectures.
Loughman et al., 51 in a cross sectional analysis involving 
some 142 young healthy subjects, observed statistically 
signi cant relationships between MPOD and best corrected 
visual acuity, and also with photopic and mesopic contrast 
sensitivity at intermediate spatial frequencies. MP appeared 
to contribute to up to a 0.1 log unit refinement of high 
contrast visual acuity (equivalent to one extra line on the 
acuity chart, or the effective correction of up to 0.25D or 
residual blur). The correlations between MPOD and visual 
acuity and contrast sensitivity however, although statistically 
significant, account for only a small percentage of the 
potential variability (r 2 values < 10 %), so should be 
interpreted cautiously with respect to its clinical relevance 
in the absence of a more rigorous placebo controlled 
supplementation study.
Bartlett and Eperjesi 52 set out to explore the effect of L 
supplementation on visual performance among healthy 
observers. Similar to their AMD trial (2007), the authors 
report no effect of supplementation on performance 
measures ranging from distance and near visual acuity, 
contrast sensitivity and photostress recovery. The results 
are somewhat unsurprising however given (a) the low dose, 
6 mg/L supplement used, (b) the basic nature of the series 
of tests employed to evaluate visual performance, and (c) 
the small number of subjects tracked over 9 months (n = 46) 
and 18 months (n = 29) across such a broad age range 
(22-73 years). Once again, their failure to record MPOD or 
serum L and Z levels means that only quali ed comment can 
be made as to the signi cance of the reported  ndings.
Armstrong et al., in a primitively designed pilot study 
(involving only one subject) presented at a recent 
conference (ARVO 2008, Poster # 4964/D984), evaluated 
macular function on a serial basis throughout a 4-month 
period of supplementation with L and Z. Looking at a series 
of psychophysical and electrophysiological outcome 
measures, they evaluated the effect of supplementation on 
dark-adapted thresholds and recovery kinetics, pattern 
visual evoked potentials (PVEPs) [before and after 
photostress], and PERG amplitude. An MPOD increase of 
approximately 33 % was accompanied by a 23 % improvement 
in 650nm dark adapted thresholds (from 30dB to 37dB) and 
by an increase in PERG amplitude, but not by a change in 
cone recovery kinetics or photostress PVEP recovery. 
Although these  ndings should be interpreted with caution, 
particularly given that only one subject was tested, they are 
again suggestive of an improvement in macular function 
following augmentation of MPOD in young healthy subjects.
The inconsistencies in spatial vision data with respect to 
MPOD re ect the dif culty inherent in isolating performance 
tasks which may be in uenced by MP. Furthermore, the wide 
inter-individual variability of MPOD 53 renders the 
interpretation of such studies all the more challenging, 
particularly where such investigations depend on 
cross-sectional rather than longitudinal data. It would 
however seem to be the case that, as far as spatial vision is 
concerned, the effect, if any, of MP on performance appears 
small, at least for individuals with average to high MPOD.
Colour vision
Since the MP absorption spectrum ranges from about 400 to 
520 nm and peaks at 460 nm, 54 it would seem likely that 
these pigments influence colour vision through selective 
absorption of short wavelengths, thereby in uencing the 
short-wave sensitive (SWS) cones and the blue-yellow 
opponent-colour channel. Moreland and Dain 55 (1995) 
reported that hue discrimination, measured using the 
Farnsworth-Munsell 100-Hue test (FM100), is indeed 
adversely affected (primarily) for blue wavelengths, by 
simulation of high MPOD using liquid notch  lters containing 
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carotene in a benzene solution. Comparing the results with 
those obtained with a neutral  lter, they concluded that 
this effect was not simply the result of reduced retinal 
illuminance. Further evidence supporting an effect of MPOD 
on short wavelength vision has been obtained from studies 
of SWS cone sensitivity. 56,57 It has also been shown that 
colour discrimination measured by a colour matching 
technique is in uenced by MPOD. 58,59
However, two recent studies using alternative methods, 
produced conclusions differing from those of the above 
mentioned studies. Firstly, a study of the effects of dietary 
supplementation with macular carotenoids on MP found no 
correlation between the level of MP (measured by 
heterochromatic  icker photometry) and red-green (RG) or 
yellow-blue (YB) colour discrimination thresholds, though it 
was reported that RG vision was improved following 
supplementation. 60 Secondly, RG cancellation pro les have 
been reported to be highly correlated with MPOD, while 
pro les for YB were independent of both eccentricity and 
MPOD. 61 Further support comes from a study of anomaloscope 
Moreland match midpoint data, in which no difference was 
reported between post-cataract patients with blue-absorbing 
intra-ocular lenses (IOLs) and those with clear IOLs. 62
Thus, the in uence, if any, of MP on colour vision remains 
uncertain at the present time. However, It is possible that 
an arti cial  lter creates short-term changes in colour vision 
and that an autoregulatory process adjusts retinal and/or 
cortical colour mechanisms on a long-term basis in response 
to an individual’s naturally occurring MPOD. 61 This hypothesis 
is supported by data showing a consistent shift in achromatic 
locus over a three month period for post-surgical cataract 
patients, 63 and by evidence of plasticity of adult neural 
colour mechanisms. 64
Preservation of ‘youthful’ vision into old age
In the elderly, pre-retinal image degradation and slower 
encoding results in featurally-compromised representation 
of spatially-extended search arrays. Even with appropriate 
optical correction, older adults therefore do not possess the 
spatial resolving power of the young adult. Such losses are 
not confined to high spatial frequencies, but contrast 
sensitivity losses are observed across a range of intermediate 
frequencies. 65 Indeed, many changes in both structure and 
function of the visual system, such as pupillary miosis and 
loss of crystalline lens transparency, 66 accompany the aging 
process (summarised elsewhere 67). The consequence of such 
changes is a reduction in retinal illuminance, such that 
equiluminant stimuli do not result in equal retinal 
illuminance for different age groups. Human visual 
performance therefore tends to decrease with age 
(Figure 4). Such effects are to some extent unavoidable, 
and a natural consequence of aging.
The most signi cant role of MP in vision, however, may 
rest on the potential of L, Z and meso-Z to retard the aging 
process through their antioxidant properties. It is important 
to note that MP acts, uniquely, as an antioxidant, both 
passively and actively, the former mechanisms being 
dependent on its ability to limit photo-oxidative damage by 
 ltering short wavelength light at a pre-receptorial level 
and the latter mechanism attributable to its capacity to 
quench reactive oxygen intermediates.
The inter-individual variability in MPOD, consistently observed 
in cross-sectional studies, may have important implications for 
the long term health and viability of the central retina. In 
subjects with little MP, the cumulative and chronic effects of 
increased exposure of photoreceptors to short wavelength 
light, coupled with a weaker local capacity to quench free 
radicals, could, in theory at least, accelerate the onset of 
physiological and pathological aging of the retina.
In support of such a notion, Hammond et al. 56 have shown 
that high MPOD was associated with the retention of youthful 
scotopic and short wave sensitivity and suggested that MP 
may retard an age-related visual decline. The potential 
bene ts of increased MPOD appear not to be con ned to the 
retina. Hammond et al. 68 reported a positive and signi cant 
association between crystalline lens transparency and 
MPOD, and speculated that high concentrations of the 
macular carotenoids in the lens probably accompany high 
concentrations at the macula, and protect against the 
effects of oxidation in the lens (thereby maintaining 
transparency). Indeed, other studies have shown an 
association between a high dietary intake of L and Z with 
decreased incidence of cataract formation. 69,70
Werner and Steele 71 demonstrated age-related sensitivity 
losses of foveal colour mechanisms across all three cone 
types, although the sensitivity loss for short wavelength 
sensitive cones (S-cone) was lower (at 0.08 log units per 
decade), when compared to 0.11 log units loss per decade 
for both medium (M-cone) and long wave (L-cone) cones. 
Werner et al. 57 later explored the senescence of foveal and 
parafoveal cone sensitivities and their relation to MPOD. 
Again, they report age-related decline of foveal and 
parafoveal increment thresholds. Interestingly however, and 
consistent with the hypothesis that the MP protects the 
photoreceptors from senescent losses in sensitivity, a 
significant and positive correlation was found between 
foveal MPOD and differential S-cone log sensitivity losses at 
the fovea and at the parafovea, but not with differential 
M- and L- cone log sensitivity losses at the retinal loci. This 
 nding, however, was independent of age, prompting the 
authors to postulate that it was due to local gain changes, 
Figure 4 Effect of normal aging on contrast sensitivity. 
Experimental data show a 1-log unit sensitivity decrease from 
age 60 to 95. Reprinted with permission: Haegerstrom-Portnoy, 
et al. 2007;79.
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resulting from differential  ltering of incident light by the 
MP between the fovea and the parafovea.
Haegerstrom-Portnoy 72 also examined S-cone versus 
L-cone sensitivity in a group of young and older adults to 
determine whether MP protects the human fovea from 
retinal neural damage caused by visible-light exposure over 
a lifetime. While there was no difference observed for 
L-cone sensitivity between groups, the older group showed 
a signi cant differential loss of S-cone sensitivity across the 
retina compared with the younger group, with greater loss 
of sensitivity at non-foveal locations than at the fovea. This 
observation is again suggestive of a protective effect of MP 
on foveal function.
Schupp et al. 73 endeavored to explore the hypothesis 
from a different perspective, postulating that if high 
levels of MP might forestall the effects of normal aging, 
then low levels of MP might accelerate the normal aging 
process. Cystic  brosis (CF) is a condition associated with 
defective gastrointestinal absorption of carotenoids as a 
result of pancreatic insuf ciency. Low serum concentra-
tions of carotenoids, including the constituents of MP, are 
invariably reported in CF patients. Given the repeatedly 
observed positive and significant relationship between 
MPOD and serum concentrations of its constituent caro-
tenoids (reviewed elsewhere 74), it can be reasoned that 
patients with CF would have low MPOD. Schupp et al. 73 
assessed visual performance in ten cystic  brosis patients, 
in whom serum concentrations of L and Z and MPOD were 
predictably and signi cantly lower than control subjects, 
and typically less than 50 % of the values observed amongst 
control subjects. However, visual performance (contrast 
sensitivity, colour discrimination and multifocal ERG 
amplitudes) were statistically similar for CF patients and 
control subjects.
While the basic rationale of this study is provocative, 
there are however a number of concerns with the 
methodology. With six of the ten CF subjects aged between 
21-27 years, it is unlikely that such a youthful population 
sample would demonstrate accelerated aging effects on 
visual function (even in the presence of chronically low 
MPOD levels). In any case, given the theoretical possibility 
that higher levels of MP might be associated with enhanced 
visual performance, it is unclear from this publication as to 
how functional differences, which might have been observed 
between the CF and control groups, could be attributable to 
age effects rather than simply to differences in MPOD. The 
authors conceded that a longitudinal assessment of an older 
CF population is required to address the hypothesis more 
appropriately.
Hammond and Wooten 75 investigated the relationship 
between MP, critical  icker fusion frequency (CFF) and age, 
citing CFF as a general measure of visual health. They found 
a signi cant decline in CFF values with age. There was a 
significant and positive relationship however between 
MPOD and CFF values that was independent of age. The 
authors conclude that these results are consistent with a 
protective effect of MP on visual health across the lifespan. 
While such investigations appear to be at a very early stage, 
preliminary results suggest a role for MP in temporal vision 
and, speci cally, that high MPOD may protect the retina 
and defer some typical age-related changes in temporal 
vision.
Conclusions
Visual performance in the normal human is less than ideal, 
and it has been shown that visual performance improves 
once chromatic and monochromatic aberrations are 
removed. 76 As a consequence, numerous interventions 
which attenuate these aberrations have been developed in 
an attempt to optimise and/or enhance visual performance, 
Wavefront-guided laser refractive eye surgery, wavefront–
guided spectacle lenses, short wavelength-filtering 
intraocular lens implants, short wavelength-filtering 
contact lenses and short wavelength filtering spectacle 
lenses are all directed towards improving or optimising 
visual performance. These techniques, however, are 
primarily intended for persons with pre-existing ocular 
abnormality or disease, and there has been a conspicuous 
lack of concerted effort to improve (or maintain) visual 
performance in subjects without demonstrable ocular 
patho logy. Augmentation of MPOD by means of supple-
mentation remains a plausible and realistic means (in 
theory at least) of optimising and/or enhancing visual 
performance in a normal population.
Future studies should address the issue of whether 
variations in MPOD relate to visual performance, and 
whether high MP levels can preserve or prolong optimal 
central visual function into old age. Indeed, some studies 
have reported that high levels of MP are associated with 
preservation of retinal sensitivity in the elderly.
MP has ideal properties, in terms of location and spectral 
absorbance, to be beneficial for visual performance and 
experience. Longer life expectancy, increased exposure to 
short wavelength light (ancestors had little or no short 
wavelength light exposure after dark), increased effects of 
scatter from expanding smog and haze, modern visual 
requirements and the ever-increasing incidence of AMD 
heightens the importance of both optimising (and possibly 
enhancing) visual performance in the working population, 
and preserving such performance into old age. Robust 
evidence, in support of the psychophysically plausible 
rationale, that MP contributes to visual performance and 
experience in a favourable way is, however, still lacking. 
The findings of the studies cited above, whether 
demonstrating a bene t of MP to visual performance and 
experience or not, should be interpreted with full 
appreciation of their design limitations, and it should be 
understood that a cross-sectional study represents an 
inappropriate design to investigate fully any contribution 
that MP makes to visual performance. It is unwise to assume 
that the role of MP in visual performance, if any, can be 
easily studied, given the multitude of typically individual 
and occasionally enigmatic factors that in uence our visual 
experience.
Given the numerous optical and neural factors that 
influence and dictate visual performance, and the 
consequential and associated difficulties in isolating 
improvements in visual performance, any study designed to 
investigate the in uence of MP in this regard should include 
questionnaire-based analyses of subject perceptions of 
personal visual experience. Such an approach will facilitate 
investigation of the potential role of MP in visual performance 
in the real world, in a natural and ever-changing 
environment, which is often poorly re ected in our current 
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and limited arsenal of testing modalities. None of the 
studies which reported a bene cial effect of MP augmen-
tation adequately address the question of (1) whether such 
increases in MPOD and the observed psychophysical 
functional improvements translate into tangible improve-
ments in visual experience outside the laboratory or (2) 
whether such improvements can be longitudinally main-
tained to preserve functional perfor mance and experience 
into old age.
Because of the inter-individual variability in MPOD and 
psychophysical visual function, a study designed to 
investigate the contribution of MP to visual performance 
and experience should be able to study the relationship 
between changes in these parameters within subjects over 
time, and only a study where MP is augmented by 
supplementation and/or dietary modi cation can meet this 
essential criterion. Interestingly, of the studies cited in this 
review, there appears to be one reasonably consistent 
 nding, despite varied design limitations, studies involving 
supplementation among normal and diseased eyes typically 
report measurable bene ts in terms of visual performance, 
in terms of photophobia thresholds, glare sensitivity, dark 
adapted thresholds, PERG amplitudes and mesopic contrast 
sensitivity among others.
Thus far, there appears to be little or no evidence of any 
adverse effect of higher levels of MP on visual performance. 
In a study designed to determine the in uence of macular 
pigment absorption on blue-on-yellow perimetry, Wild and 
Hudson 77 found that the net effect of ocular media and MP 
absorption relative to 460 nm was to attenuate the 
blue-on-yellow visual  eld at the fovea by approximately 
0.80 log units and elsewhere by 0.40 log units, the difference 
being attributable to MP. Unpublished results from our own 
laboratory suggest no association between MPOD and colour 
matching or colour discrimination ability, although we have 
observed a non-significant inverse association between 
central short wavelength sensitivity and MPOD (data on  le). 
The possibility of an adverse effect of MP augmentation on 
colour vision, short wavelength sensitivity and other 
functional measures does merit future investigation.
The optical, physiological and neurological interactions 
that contribute to vision suggest that the optimal level of 
MPOD, from a performance perspective, may be personal to 
an individual eye. In other words, and for example, even if 
MP is found to be important for visual performance and 
experience, exceeding a particular optical density of the 
pigment may yield no further measurable or appreciable 
advantage, and this level may vary substantially from one 
individual to the next. It is also important to note that 
testing conditions are often incapable of re ecting more 
natural environments, and any observed absence or presence 
of MP’s contribution to visual performance and experience 
may not necessarily hold true in a natural environment (for 
example, against the background of a bright blue sky).
Although it remains difficult to draw firm conclusions 
regarding the relationship between MP and visual 
performance, certain patterns do appear to exist. In normal 
observers, the effect on spatial and colour vision appears 
small in comparison to the observed effects on photophobia 
and glare sensitivity, while, in subjects with established eye 
disease, there appears a relatively consistent beneficial 
effect of MP supplementation on visual performance. Any 
effects observed, whether through optical or biological 
mechanisms, may also be magnified when increased 
emphasis is afforded to those with chronically low MPOD 
levels. We need and should support an appropriately 
powered, randomised, controlled trial, which is designed to 
further evaluate whether visual performance and experience 
can be optimised or enhanced, or indeed adversely affected, 
with supplemental macular carotenoids.
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